DMPI Financials 07/16/2014 12:28:41 DelMar Pharma

DMPI Financials 07/16/2014 12:28:41
DelMar Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Jun 30, 2012 Dec 31, 2011
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 2,343 1,550 - 1,051
Sales, General and Admin. 3,952 1,155 19 242
Non-Recurring Items - - - -
Other - - - -
Operating Income (6,295) (2,705) (19) (1,293)
Income From Continuing Operations
Add'l Income/Expense Items (1,988) 312 - (18)
Earnings Before Interest and Tax (8,283) (2,393) (19) (1,311)
Interest Expense 8 8 - 22
Earnings Before Tax (8,291) (2,400) (19) (1,333)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (8,291) (2,400) (19) (1,333)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (8,291) (2,400) (19) (1,333)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (8,291) (2,400) (19) (1,333)